Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tempus AI
TEM
5
Block
XYZ
US Stock MarketDetailed Quotes
Royalty Pharma (RPRX)
- 39.550
- -0.170-0.43%
Close Jan 16 15:59 ET
- 39.510
- -0.040-0.10%
Post 16:43 ET
16.90BMarket Cap22.60P/E (TTM)
39.780High39.352Low1.95MVolume39.720Open39.720Prev Close76.99MTurnover0.53%Turnover Ratio20.71P/E (Static)427.25MShares41.70052wk High2.63P/B14.57BFloat Cap28.99452wk Low0.87Dividend TTM368.40MShs Float49.967Historical High2.20%Div Yield TTM1.08%Range %23.459Historical Low39.538Avg Price1Lot Size
Royalty Pharma (RPRX) Key Financial Indicators
RPRX Earnings per Share (EPS)
According to the latest financial report of Royalty Pharma, the latest earnings per share (TTM) for the company is 0.67. Investing in companies with strong earnings per share can potentially provide higher returns.
Currency: USD
Quarterly
Loading...
RPRX Free Cash Flow (FCF)
Interested in knowing about Royalty Pharma's free cash flow? The latest report shows it as 702.62M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
Currency: USD
Quarterly
Loading...
RPRX Current Ratio
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of Royalty Pharma shows that the company's current ratio is 3.48, indicating healthy liquidity.
Currency: USD
Quarterly
Loading...
RPRX Quick Ratio
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of Royalty Pharma, the quick ratio is 3.47, indicating that the company can meet its short-term debt obligations.
Currency: USD
Quarterly
Loading...
RPRX Return on Equity (ROE)
Want to learn more about the financial health of Royalty Pharma? The latest ROE figure is 4.52%, indicating that the company has stable profitability.
Currency: USD
Quarterly
Loading...
RPRX Return on Assets (ROA)
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of Royalty Pharma, the total asset return on investment (ROA) is 1.53%.
Currency: USD
Quarterly
Loading...
RPRX Gross Margin
Gross margin can provide insight into a company's pricing strategy and cost structure. Check Royalty Pharma's latest financial report to see how their gross margin is doing - currently at --.
Currency: USD
Quarterly
Loading...
RPRX Net Margin
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of Royalty Pharma, the net profit margin is 72.91%, which is a good sign for its profitability.
Currency: USD
Quarterly
Loading...
Market Insights
Nancy Pelosi Portfolio Nancy Pelosi Portfolio
Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns. Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns.
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
The Fed Delivers Third Consecutive Rate Cut as Expected! How to Position for Year-End U.S. Equity Ma
On December 19, the Bank of Japan raised interest rates by 25 basis points as expected, in line with market forecasts. On the evening of Dec
今日熱門
Dec 11, 2025 03:27
December FOMC Interest Rate Meeting
牛牛課堂
Dec 19, 2025 12:28
[Opportunity Express] MRVL Continues to Bet on Optical Interconnects: Is Now a Good Time to Enter the Market?